Ferroptosis Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ferroptosis is an iron-dependent form of regulated cell death characterized by lipid peroxidation. Ferroptosis inhibitors represent a novel therapeutic strategy for neurodegenerative diseases, as this cell death pathway has been implicated in Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS.
Ferroptosis is a non-apoptotic cell death process characterized by:
- Iron-dependent accumulation of lipid reactive oxygen species (ROS)
- Glutathione peroxidase 4 (GPX4) inactivation
- Lipid peroxidation of membrane phospholipids
- Distinct morphological features (no nuclear fragmentation)
GPX4-dependent pathway:
- GPX4 reduces lipid peroxides to prevent ferroptosis
- System Xc- imports cystine for glutathione synthesis
- Glutathione is required for GPX4 function
Iron metabolism:
- Iron catalyzes Fenton reactions generating ROS
- Ferritin stores iron to prevent toxicity
- Transferrin receptor regulates iron uptake
Ferroptosis contributes to:
- Neuronal death in AD brain
- Iron accumulation in AD brain
- Lipid peroxidation in neurons
Inhibitors may:
- Protect neurons from death
- Reduce oxidative damage
- Slow disease progression
Ferroptosis in PD:
- Iron accumulation in substantia nigra
- Dopaminergic neuron vulnerability
- Lipid peroxidation in PD brain
Inhibitors show:
- Protection of dopaminergic neurons
- Reduced iron-induced toxicity
- Improved motor function
Ferroptosis in HD:
- Mutant huntingtin affects iron metabolism
- Enhanced neuronal vulnerability
- Lipid peroxidation in striatum
Inhibitors:
- Reduce mutant huntingtin toxicity
- Protect striatal neurons
Ferroptosis in ALS:
- Motor neuron vulnerability
- Iron dysregulation
- Enhanced oxidative stress
Inhibitors:
- Protect motor neurons
- Delay disease progression
¶ Drug Candidates
| Compound |
Mechanism |
Stage |
Company |
| Ferrostatin-1 |
Lipid ROS scavenger |
Preclinical |
N/A |
| Liproxstatin-1 |
Liproxstatin-1 |
Preclinical |
N/A |
| SRS6-16 |
GPX4 activator |
Preclinical |
N/A |
| Vitamin E |
Antioxidant |
Phase 2 |
Various |
| Deferoxamine |
Iron chelator |
Phase 2 |
Various |
| Deferasirox |
Iron chelator |
Phase 2 |
Novartis |
- NCT03225893: Deferoxamine for Alzheimer's disease (completed)
- NCT03716570: Iron chelation for Parkinson's disease (completed)
¶ Challenges and Limitations
- BBB penetration: Ensuring CNS delivery
- Iron homeostasis: Balancing iron chelation
- Optimal timing: Treatment window
- Selectivity: Targeting specific neuronal populations
- Development of brain-penetrant ferroptosis inhibitors
- Combination with antioxidants
- Gene therapy approaches
- Biomarker development
The study of Ferroptosis Inhibitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.